Ranbaxy Appoints Dr. Kathleen A. Spreen as Medical Director
PRINCETON, N.J., May 5 /PRNewswire/ -- Ranbaxy USA Inc., (RUSA), a wholly
owned subsidiary of Ranbaxy Laboratories Limited (RLL), has selected Kathleen
A. Spreen, DO, MS, MPH, to be Executive Director of Medical and Clinical
Affairs. Dr. Spreen comes to Ranbaxy from ICON Clinical Research, Inc. (North
Wales, PA), a subsidiary of ICON plc , where she served as Senior Director of
Medical Affairs. As Medical Director of RUSA, Dr. Spreen's responsibilities
will include providing medical expertise for strategic and business planning,
managing medically related issues, overseeing quality and supervising medical
staff.
Commenting on the appointment, Jeffrey Thomas, Vice president, Brand Marketing
and Sales at Ranbaxy USA, Inc., said, "Dr. Spreen is a highly-skilled and
experienced professional with a wide breadth of pharmaceutical industry
knowledge and experience. As our medical director, she will help to strengthen
Ranbaxy's position in the U.S. as an innovative and medically advanced
pharmaceutical manufacturer. Her expertise will serve as an invaluable
cornerstone for Ranbaxy's continued upward growth." Prior to her work at ICON, Dr. Spreen served as Vice President, Scientific
Services, at ApotheCom Associates (Yardley, PA) where she led a team of
scientific writers, editors and biostatisticians and managed client relations. Before ApotheCom, Dr. Spreen was the Senior Director of Clinical Research, GI
Therapeutic Area at AstraZeneca Pharmaceuticals (Frazier, PA), and earlier,
worked at Johnson & Johnson, Wyeth-Ayerst and DuPont-Merck. She served in the
U.S. Army Medical Corps in the mid-1980s, finishing her tour as Deputy
Commander for Clinical Services at the Kirk U.S. Army Health Clinic (Aberdeen
Proving Ground, MD).
Dr. Spreen received her DO in 1983 from the Philadelphia College of Osteopathic
Medicine. She earned her Masters of Public Health Degree at the Medical
College of Wisconsin in 1992. That same year, she was Board Certified in
Preventive and Occupational Medicine by the American Osteopathic Board of
Preventive Medicine. In 1995, she received her Board Certification in Family
Practice from the American Osteopathic Board of Family Physicians.
Dr. Spreen is widely published and has lectured and provided testimony
extensively, particularly in the areas of occupational health and cost
effectiveness. Among her memberships in many professional and scientific
organizations, Dr. Spreen is a member of the American Osteopathic Association,
the American Osteopathic College of Preventive Medicine, the Medical Society of
Delaware, the American Medical Association, the American College of Physician
Executives, the American Academy of Pharmaceutical Physicians and the Society
of Clinical Research Associates.
ABOUT RANBAXY LABORATORIES LIMITED Ranbaxy Laboratories Limited, India's largest pharmaceutical company,
manufactures and markets brand and generic pharmaceuticals and Active
Pharmaceutical Ingredients. Ranbaxy's continued focus on R&D has resulted in
several approvals in developed markets and significant progress in New Drug
Discovery Research. Ranbaxy's foray into Novel Drug Delivery Systems has led to
proprietary "platform technologies" resulting in a number of products under
development. The Company is selling its products in over 100 countries and has
an expanding international portfolio of affiliates, joint ventures and
alliances, ground operations in 34 countries and manufacturing operations in 7
countries. DATASOURCE: Ranbaxy Pharmaceuticals CONTACT: Charles M. Caprariello, Vice President, Business Development of Ranbaxy Inc., +1-609-720-5615; Janine Lang of RF Binder Partners, +1-212-994-7525, for Ranbaxy
|